Dog DNA testing startup Embark raises $75 million in second funding round
Embark Veterinary, Inc. announced this morning that it has raised $75 million in Series B funding, a term often used by bankers to describe the second round. According to the company’s press release, it represents the largest cash injection for a pet industry startup in its second round. TCR has not independently verified that claim.
Embark maintains that its “long-term goal” is to “increase the lifespan of dogs by three years within the next decade.”
Embark will use the new funding to expand on key hires and accelerate the development of its robust discovery engine. As Embark’s database expands, the company will be able to exponentially increase the number of novel discoveries it makes to help dogs live healthier, longer lives. All of this will support Embark’s long-term goal to increase the lifespan of dogs by three years within the next decade.